Activity of telithromycin against penicillin-resistant Streptococcus pneumoniae isolates recovered from French children with invasive and noninvasive infections

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 7, 2003, Pages 2345-2347

  Bingen, Edouard ^a   Doit, Catherine ^a   Loukil, Chawki ^a   Brahimi, Naima ^a   Bidet, Philippe ^a   Deforche, Dominique ^a   Geslin, Pierre ^b  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CEFPODOXIME; CEFTRIAXONE; ERYTHROMYCIN; JOSAMYCIN; PENICILLIN G; TELITHROMYCIN;

ARTICLE; BACTERIUM ISOLATE; CHILD; DRUG ACTIVITY; FRANCE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CEFTIZOXIME; CEFTRIAXONE; CHILD; DRUG RESISTANCE, BACTERIAL; ERYTHROMYCIN; FRANCE; HUMANS; JOSAMYCIN; KETOLIDES; MACROLIDES; PENICILLIN G; PENICILLIN RESISTANCE; PENICILLINS; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 0037974578     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.7.2345-2347.2003     Document Type: Article

References (34)

1. Angot, P., M. Vergnaud, M. Auzou, and R. Leclerc. 2000. Macrolide resistance phenotypes and genotypes in French clinical isolates of Streptococcus pneumoniae. Eur. J. Microbiol. Clin. Infect. Dis. 19:755-758.
2. Appelbaum, P. C. 2002. Resistance among Streptococcus pneumoniae: implications for drug selection. Clin. Infect. Dis. 34:1613-1620.
3. Bryskier, A. 1999. Kétolides, p. 563-594. In A. Bryskier (ed.), Antibiotiques agents antibactériens et antifongiques. Ellipses Marketing S.A., Paris, France.
4. Bryskier, A. 2000. Ketolides - telithromycin, an example of a new class of antibacterial agents. Clin. Microbiol. Infect. 6:661-669.
5. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
6. Davies, T. A., L. M. Ednies, D. M. Hoellmon, G. A. Pankuch, M. R. Jacobs, and P. C. Appelbaum. 2000. Antipneumococcal activity of ABT-773 compared to those of 10 other agents. Antimicrob. Agents Chemother. 44:1894-1899.
7. Doern, G. V., P. K. Heilmann, H. K. Huynh, P. R. Rhomberg, S. L. Coffman, and A. B. Brueggemann. 2001. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in the United States during 1999-2000, including a comparison of resistance rates since 1994-1995. Antimicrob. Agents Chemother. 45:1721-1729.
8. Doit, C., C. Loukil, F. Fitoussi, P. Geslin, and E. Bingen. 1999. Emergence in France of multiple clones of clinical Streptococcus pneumoniae isolates with high-level resistance to amoxicillin. Antimicrob. Agents Chemother. 43:1480-1483.
9. Doit, C., C. Loukil, P. Geslin, and E. Bingen. 2002. Phenotypic and genetic diversity of invasive pneumococcal isolates recovered from French children. J. Clin. Microbiol. 40:2994-2998.
10. Doit, C., B. Picard, C. Loukil, P. Geslin, and E. Bingen. 2000. Molecular epidemiology survey of penicillin-susceptible and -resistant Streptococcus pneumoniae recovered from patients with meningitis in France. J. Infect. Dis. 181:1971-1978.
11. Farrell, D. J., I. Morrissey, S. Bakker, and D. Felmingham. 2002. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the Protekt 1999-2000 study. J. Antimicrob. Chemother. 50(Suppl. S1):39-47.
12. Fitoussi, F., C. Doit, P. Geslin, N. Brahimi, and E. Bingen. 2001. Mechanisms of macrolide resistance in clinical pneumococcal isolates in France. Antimicrob. Agents Chemother. 45:6363-438.
13. Fogarty, C., R. Goldschmidt, and K. Bush. 2000. Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and clarithromycin. Clin. Infect. Dis. 31:613-615.
14. Gehanno, P., A. Panajotopoulos, B. Barry, L. Nguyen, D. Levy, E. Bingen, and P. Berche. 2001. Microbiology of otitis media in the Paris, France, area from 1987 to 1997. Pediatr. Infect. Dis. J. 20:570-573.
15. Guillemot, D., P. Maison, C. Carbon, B. Balkau, F. Vauzelle-Kevroëdan, C. Sermet, G. Bouvenot, and E. Eschwège. 1998. Trends in antimicrobial drug use in the community-France, 1981-1992. J. Infect. Dis. 177:492-497.
16. Hamilton-Miller, J. M., and S. Shah. 1998. Comparative in vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status. J. Antimicrob. Chemother. 41:649-653.
17. Hyde, T. B., K. Gay, D. S. Stephens, D. J. Vugia, M. Pass, S. Johnson, N. L. Barrett, W. Schaffner, P. R. Cieslak, P. S. Maupin, E. R. Zell, J. H. Jorgensen, R. R. Facklam, and C. G. Whitney. 2001. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 286:1857-1862.
18. Jackson, M. A., V. F. Burry, L. C. Olson, S. E. Duthie, and G. L. Kearns. 1996. Breakthrough sepsis in macrolide-resistant pneumococcal infection. Pediatr. Infect. Dis. J. 15:1049-1051.
19. Jacobs, M. R. 2001. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin. Microb. Infect. 11:589-596.
20. Johnson, C. N., W. H. Benjamin, Jr., B. M. Gray, M. C. Crain, K. M. Edward, and K. B. Waites. 2001. In vitro activity of ABT-773, telithromycin and eight other antimicrobials against erythromycin-resistant Streptococcus pneumoniae respiratory isolates of children. Int. J. Antimicrob. Agents 18:531-535.
21. Kelley, M. A., D. J. Weber, P. Gilligan, and M. S. Cohen. 2000. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin. Infect. Dis. 31:1008-1011.
22. Klugman, K. P., T. Capper, C. A. Widdowson, H. J. Koornhof, and W. Moser. 1998. Increased activity of 16-membered lactone ring macrolides against erythromycin-resistant Streptococcus pyogenes and Streptococcus pneumoniae: characterization of South African isolates. J. Antimicrob. Chemother. 42:729-734.
23. Leclercq, R. 2002. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. Dis. 34:482-492.
24. Low, D. E., J. Azavedo, K. Weiss, T. Mazzulli, M. Kuhn, D. Church, K. Forwars, G. Zhanel, A. Simor, Canadian Bacterial Surveillance Network, and A. McGeer. 2002. Antimicrobial resistance among clinical isolates of Streptococcus pneumoniae in Canada during 2000. Antimicrob. Agents Chemother. 46:1295-1301.
25. Mason, E. O., Jr., L. B. Lamberth, N. L. Kershaw, B. L. Prosser, A. Zoe, and P. G. Ambrose. 2000. Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis. J. Antimicrob. Chemother. 45:623-631.
26. McIntosh, K. 2002. Community-acquired pneumonia in children, N. Engl. J. Med. 346:429-437.
27. Morosini, M. I., R. Canton, E. Loza, M. C. Negri, J.-C. Galan, F. Almaraz, and F. Baquero. 2001. In vitro activity of telithromycin against Spanish Streptococcus pneumoniae isolates with characterized macrolide resistance mechanisms. Antimicrob. Agents Chemother. 45:2427-2431.
28. Namour, P., D. H. Wessels, M. H. Pascul, D. Reynolds, E. Sultan, and B. Lenfant. 2001. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob. Agents Chemother. 45:170-175.
29. National Committee for Clinical Laboratory Standards. 2000. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
30. National Committee for Clinical Laboratory Standards. 2002. Performance standards for antimicrobial susceptibility testing. Twelfth informational supplement. NCCLS document M100-S12. National Committee for Clinical Laboratory Standards, Wayne, Pa.
31. Pankuch, G. A., M. A. Visalli, M. R. Jacobs, and P. A. Appelbaum. 1998. Susceptibility of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob. Agents Chemother. 42:624-630.
32. Reid, R., J. S. Bradley, and J. Hindler. 1995. Pneumococcal meningitis during therapy of otitis media with clarithromycin. Pediatr. Infect. Dis. J. 14:1104-1105.
33. Sutcliffe, J., T. Grebe, A. Tait-Kamrath, and L. Worndrack. 1996. Detection of erythromycin-resistant determinant by PCR. Antimicrob. Agents Chemother. 40:2562-2566.
34. Weiss, K., C. Guillault, L. Cortes, C. Restieri, and D. E. Low. 2002. Genotypic characterization of macrolide-resistant strains of Streptococcus pneumoniae isolated in Quebec, Canada, and in vitro activity of ABT-773 and telithromycin. J. Antimicrob. Chemother. 50:403-406.